A novel biomimetic nanozyme orchestrates ulcerative colitis resolution by targeting KEAP1-NRF2-ARE pathway: Redox balance restoration, colonic barrier repair, immune homeostasis regulation.

ABSTRACT: Ulcerative colitis (UC) leads to systemic complications with excessive oxidative stress, colonic barrier damage, and inflammation. Deuterohemin-AlaHisThrValGluLys (DhHP-6) is the biomimetic nanozyme rationally designed to mimic the peroxidase activity of Microperoxidase-11. It exhibits potent antioxidant properties, which might emerge as a promising therapeutic candidate compound for UC. In this paper, we aimed to probe the therapeutic effects of DhHP-6 on UC and clarify the underlying molecular mechanisms. We employed dextran sulfate sodium-induced C57BL/6 J male mice for in vivo studies. Lipopolysaccharides-induced intestinal epithelial (Caco-2) and macrophage (RAW264.7) cells were established for in vitro studies. Immunofluorescence, reactive oxygen species (ROS) assays we

SUBMITTER: Gong P 

PROVIDER: S-EPMC12756036 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature